-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Fussen Pharmaceutical (01652.HK) announced that the marketing application for “Doxazosin Mesylate Sustained Release Tablets” (trademark: Yi Jianping) developed by Henan Fuson Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, has been approved by the China Drug Administration and approved for symptomatic treatment of hypertension and benign prostatic hyperplasia.

Zhitongcaijing·07/10/2026 12:17:10
Listen to the news
Zhitong Finance App News, Fussen Pharmaceutical (01652.HK) announced that the marketing application for “Doxazosin Mesylate Sustained Release Tablets” (trademark: Yi Jianping) developed by Henan Fuson Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, has been approved by the China Drug Administration and approved for symptomatic treatment of hypertension and benign prostatic hyperplasia.